Clinical Trial News and Research

RSS

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

Gut microbiome characteristics predict treatment response in IBS-D patients

In a new study published in Clinical Gastroenterology and Hepatology, the low FODMAP diet and the antibiotic rifaximin provided similar and significant relief for patients with irritable bowel syndrome with diarrhea (IBS-D).

22 Apr 2026

Immunotherapy drug helps bladder cancer patients avoid major organ removal

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

22 Apr 2026

Rapid blood infection test fails to improve survival

Rapid antimicrobial susceptibility testing for gram-negative blood infections shows no improvement in clinical outcomes compared to standard testing methods.

22 Apr 2026

Tumor immune cell patterns predict melanoma immunotherapy response

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

22 Apr 2026

New molecule weakens glioblastoma and enhances immune response

A team of researchers from Brown University Health and Brown University has uncovered an important clue in the fight against glioblastoma, the most common and aggressive form of brain cancer in adults.

21 Apr 2026

Low-dose nivolumab injections shrink precancerous oral lesions

Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from surgery.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Injectable immunotherapy shrinks precancerous oral lesions in clinical trial

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Alzheimer’s monoclonal antibodies fail to deliver meaningful results

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches.

21 Apr 2026

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last visit (LPLV) has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.

From AlzeCure Pharma AB 21 Apr 2026

Ibuprofen shown to improve cognitive function in patients undergoing chemotherapy

Researchers have already shown that mild to moderate exercise can reduce "chemo brain," and a new study suggests that a low dose of an over-the-counter anti-inflammatory, ibuprofen, can also achieve positive results for cancer patients.

21 Apr 2026

Phase I NSCLC trials shrink and cluster in major U.S. cities

Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest‑volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

21 Apr 2026

Trial shows safety of novel KIR-CAR T therapy in solid tumors

An innovative type of CAR T cell therapy, called KIR-CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine patients with advanced ovarian cancer, mesothelioma or cholangiocarcinoma (bile duct cancer), according to an early report from an ongoing Phase I dose-escalation clinical trial.

20 Apr 2026

Trial shows durable response with preoperative immunotherapy in bowel cancer

Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and UCLH.

20 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

AI model predicts immunotherapy response in lung cancer patients

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026